- U.S. stock futures declined sharply during Tuesday's pre-market session, with Dow futures falling over 400 points.
- Novartis shares tumbled 12.7 % after reporting that its pelacarsen phase III Lp(a) HORIZON trial failed to meet its primary endpoint.
- Other notable movers included Ionis Pharmaceuticals dropping 11.5 % in sympathy and Dyne Therapeutics dipping 35.5 %.